- This event has passed.
An Author Webinar on the Neuropsychiatric Inventory (NPI) Questionnaire
November 9, 2016 @ 11:00 - 12:00 UTC+0
An Author Webinar on the Neuropsychiatric Inventory (NPI) Questionnaire
Webinar Date & Time:
Wednesday, November 9, 2016 at
- 8:00 am - 9:00 am PST (San Fransisco, CA)
- 11:00 am - 12:00 pm EST (New York, USA)
- 4:00 pm - 5:00 pm GMT (London, UK)
- 5:00 pm - 6:00 pm CET (Paris, FR)
Dr. Jeffrey L. Cummings, M.D., Sc.D. - Author of the NPI Questionnaire; Specializes in Neurology
- Jeffrey L. Cummings, MD, ScD, is Director, Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas, Nevada and Cleveland, Ohio. He is the Camille and Larry Ruvo Chair of the Neurological Institute of Cleveland Clinic and Professor of Medicine (Neurology), Cleveland Clinic Lerner College of Medicine of Case Western Reserve University.
- Dr. Cummings is Principal Investigator/Director of the NIH/NIGMS-funded Center for Neurodegeneration and Translational Neuroscience.Dr. Cummings is a world-renowned Alzheimer’s researcher and leader of clinical trials. He has been recognized for his research and leadership contributions in the field of Alzheimer’s disease through the Henderson Award of the American Geriatrics Society (2006), the Research Award of the John Douglas French Alzheimer’s Research Foundation (2008), and the Ronald and Nancy Reagan Research Award of the national Alzheimer’s Association (2008). In 2010, he was honored by the American Association of Geriatric Psychiatry with their Distinguished Scientist Award. In 2011, he was awarded a Doctor of Science by his Alma mater, University of Wyoming. He was featured in the Gentleman’s Quarterly (June 2009) as a “Rockstar of Science."
- Dr. Cummings was formerly Professor of Neurology and Psychiatry at UCLA, director of the Mary S. Easton Center for Alzheimer’s Disease Research at UCLA, and director of the Deane F. Johnson Center for Neurotherapeutics at UCLA. He is past president of the Behavioral Neurology Society and of the American Neuropsychiatric Association.
- Dr. Cummings has authored or edited 39 books and published over 650 peer-reviewed papers.
Christelle Giroudet - Language Services, Mapi Group
Neuropsychiatric symptoms are common findings in Alzheimer’s disease and other neurological disorders. Quantification of these symptoms is critical to advancing a scientific understanding of their epidemiology, biology, and response to interventions.
Dr. Cummings created and published the Neuropsychiatric Inventory (NPI) in 1994 and it has since been used in hundreds of articles. It has been used to show the high prevalence of neuropsychiatric symptoms among dementing disorders including Alzheimer’s disease, frontotemporal dementia, dementia with Lewy bodies, vascular dementia, traumatic brain injury, progressive supranuclear palsy, corticobasal degeneration, and others.
The NPI has been used to quantify the cost of behavioral disturbances in residential settings. It has been used in multiple biological studies to show the relationship of changes in cortical brain regions to neuropsychiatric symptoms. The relationship between biological alterations in the medial frontal regions of the cortex and the prevalence of apathy, for example, has been confirmed on studies of cortical brain thickness, neuropathology at autopsy, and hypometabolism on positron emission tomography.
The NPI has been used in many clinical trials and is the principle outcome measure used in clinical trials of behavioral disturbances in neuropsychiatric symptoms.
More details will be discussed regarding the NPI questionnaire and it's usage during this webinar. Register now!
- Cummings, MD Jeffrey L
- NPI © Dr. Cummings, 1994, All rights reserved.
The Questionnaire's Objective
- The NPI has served as an outcome measure in many pharmacologic and nonpharmacologic intervention studies.
- NPI and NPI-NH: To assess changes in the patient's behavior that have appeared since the onset of the dementia.
- NPI-Q: To identify clinically significant neuropsychiatric disturbances and their associated impact on caregivers.
- NPI-C: Developed for expert clinicians; can be considered when the interviewer is an expert psychiatric/behavioral interviewer.
- Original version developed in 1994. Also exists in a 10-item version.
- NPI-NH: Nursing Home Version for use in institutional settings.
- NPI-Q: Brief clinical form.
- NPI-C: Clinician version structured to allow experts to have structured input to the NPI rating.
- Nervous System Diseases
>> COA type depending on the version of the questionnaire
- English - USA
- 30 Minute PowerPoint Presentation
- 30 Minute Question & Answer (Q&A) Session
Learn more about the NPI Questionnaire on ePROVIDE:
Register to attend this webinar now (don't delay, limited seats available):
September 20 @ 10:00 - 11:00 UTC+0
Patient Insights & Engagement Webinar – Creating Tools that are Share-worthy: Encouraging Patient Centricity throughout the OrganizationAugust 31, 2018 @ 10:00 - 11:00 UTC+0
- A Real World Strategy & Analytics Webinar: Challenges and solutions for Risk Management Plan (RMP) Effectiveness Studies
- An Author Webinar on the Disease Activity Score (DAS/DAS-28)
- Rare Disease Webinar: SYNGAP Education & Research – Collaboration & Data sharing as Keys to Progress
- Direct to Patient Contact Webinar: How Routine Patient Contact Reduces Patient Loss & Costs in Long-Term Studies
- RAPS Philadelphia Chapter Regulatory Webinar: Pitfalls to Avoid for CMC Postapproval Changes
- PCO Accept Webinar: Do you know how motivated patients affected by multiple sclerosis are to take treatment & why they are not?
- Database Analyses: Linking Administrative Registries with Clinical Registries
- Health Policy Initiatives: Ideas Becoming Official Policy and Beyond
- View All Archived Webinars
- Forúm Assistência Farmacêutica e Farmacoeconomia / V Brazilian Forum On Pharmaceutical Assistance And Pharmacoeconomics: The Financing Of Pharmaceutical Assistance In Times Of Crisis
- ISPE’s 33rd International Conference on Pharmacoepidemiology (ICPE) & Therapeutic Risk Management 2017
- ISCTM 2017 Autumn Conference
- PCO Webinar – Developing PROs to support labelling claims, especially for rare diseases/specialty products
- 2017 RAPS Regulatory Convergence
- PCO ACCEPT Webinar Series – Session 3: Do you know how much patients affected by Rheumatoid Arthritis or Crohn’s Disease or Psoriasis are motivated to take treatment and why they are not?
- Mapi and Saama Create Actionable Solutions From Recent Strategic Alliance
- Press Release: Mapi Creates Dedicated Patient Centered Sciences Unit by Combining Patient Centered Outcomes, Patient Insights and Engagement and Direct To Patient Contact Services
- Mapi Research Trust and Mapi Language Services present scientific research works at the International Congress of Parkinson’s Disease and Movement Disorders (MDS)
- Press Release: Mapi Continues Organic Growth and Expansion in the United Kingdom
- Mapi Research Trust selected as exclusive distributor and Mapi Language Services selected as exclusive translator of the Disability Assessment for Dementia (DAD)